What recent development has helped Novo Nordisk regain momentum against Eli Lilly in the obesity drug race?

Novo Nordisk's newly launched oral Wegovy weight-loss pill—launched in the U.S. in January—has held onto its lead against Eli Lilly's recently launched Foundayo (orforglipron), providing a boost despite Novo's prior loss of ground in injectable GLP-1s and a bruising two-year period marked by profit warnings, leadership upheaval, and share price declines.

Why is the upcoming August 5 second-quarter earnings report significant for Novo Nordisk?

Analysts and shareholders will look to Novo Nordisk's August 5 second-quarter results for clues on whether its turnaround is durable and whether it can keep pace with Eli Lilly over the longer term—especially as the company seeks to rebound from four guidance cuts in 2025, a CEO replacement, a 9,000-job restructuring, and a recent heart disease drug trial failure.

Novo Nordisk Regains Momentum in Obesity Drug Race Against Eli Lilly

Aug 2, 2026

Novo Nordisk shares climbed 35% as its oral Wegovy competes strongly against Eli Lilly's Zepbound in the projected $100 billion obesity market. Investors await Q2 results to assess the durability of this turnaround amid pricing pressures and legal disputes.

reuters

2026-02-25

Novo Nordisk Taps Start-Up for New Oral Weight-Loss Drugs

2026-04-13

Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development

2026-04-23

Novo Nordisk's Oral GLP-1 Drug Meets Primary Goal in Late-Stage Diabetes Study

2026-05-05

Novo Nordisk's first-quarter profit beats forecasts

2026-05-26

Global Firms Bring More Work In-House at India Hubs on AI Boost